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Abstract
Background: Novel precision oncology trial designs, such as basket and umbrella trials, are designed to test new
anticancer agents in more effective and affordable ways. However, they present some ethical concerns referred to
scientific validity, risk-benefit balance and informed consent. Our aim is to discuss these issues in basket and
umbrella trials, giving examples of two ongoing cancer trials: NCI-MATCH (National Cancer Institute – Molecular
Analysis for Therapy Choice) and Lung-MAP (Lung Cancer Master Protocol) study.
Main body: We discuss three ethical requirements for clinical trials which may be challenged in basket and umbrella
trial designs. Firstly, we consider scientific validity. Thanks to the new trial designs, patients with rare malignancies have
the opportunity to be enrolled and benefit from the trial, but due to insufficient accrual, the trial may generate
clinically insignificant findings. Inadequate sample size in study arms and the use of surrogate endpoints may result in
a drug approval without confirmed efficacy. Moreover, complexity, limited quality and availability of tumor samples
may not only introduce bias and result in unreliable and unrepresentative findings, but also can potentially
harm patients and assign them to an inappropriate therapy arm. Secondly, we refer to benefits and risks. Novel clinical
trials can gain important knowledge on the variety of tumors, which can be used in future trials to develop effective
therapies. However, they offer limited direct benefits to patients. All potential participants must wait about 2 weeks for
the results of the genetic screening, which may be stressful and produce anxiety. The enrollment of patients whose
tumors harbor multiple mutations in treatments matching a single mutation may be controversial. As to informed
consent – the third requirement we discuss, the excessive use of phrases like “personalized medicine”, “tailored
therapy” or “precision oncology” might be misleading and cause personal convictions that the study protocol is
designed to fulfill the individual health-related needs of participants.
Conclusions: We suggest that further approaches should be implemented to enhance scientific validity, reduce
misunderstandings and risks, thus maximizing the benefits to society and to trial participants.
Keywords: Umbrella trial, Basket trial, Master protocol, NCI-MATCH, Lung-MAP, Scientific validity, Risk-benefit
balance, Informed consent, Ethics
Background
The current move to genomics changes the diagnostic
information needed for treatment and belongs to a novel
concept of personalized or precision medicine [1]. Its
aim is to use tailored therapies to target specific genetic
changes that cause the tumor to develop. Thanks to the
understanding of each person’s cancer at the molecular
level, it can be possible to adjust the appropriate drug
and dose, thus maximizing the benefit of targeted treat-
ment for the individual [1, 2].
Development of new medicines that work only on a
specific type of malignancy, or more specifically, on a
particular genetic abnormality, requires new approaches
to conducting clinical trials. The American Food and
Drug Administration (FDA) encourages implementing
innovative clinical trial designs like umbrella trials or
basket trials as they give hope for better treatments and
very effective drugs, but according to us, they also
present ethical challenges. For instance, if we consider a
classic approach by Emanuel et al. [3] at least three eth-
ical requirements must be analyzed: scientific validity,
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favorable risk-benefit ratio and informed consent. We
narrow down our discussion to basket and umbrella tri-
als in oncology, which is a limitation of our study, but
some of our considerations can possibly be applied to
other contexts.
Before we refer to the main considerations, we briefly
describe these types of trials and give an example of each
in order to give a basis for further reflections.
Master protocols: basket trials and umbrella trials
Master protocol is a research process designed to test
multiple targeted therapies in small sub-trials or cohorts
[2, 4]. Patients with cancer are assigned to an arm of a
clinical trial based on their targeted abnormality found
in the tumor [2]. A flexible structure allows for adding
more arms over time and the ineffective ones can be
closed, without writing a new protocol [5]. We can dis-
tinguish two main types of master protocols: a basket
trial and an umbrella trial (Fig. 1).
Basket trial
A basket trial enrolls patients with any cancer type (e.g.,
colon, breast, lung and others) but who share the same
genetic abnormality (Fig. 1) [6]. Generally, it can be a
single- or multiple-arm trial, in which one arm is a sep-
arate “basket” that assigns small cohorts of patients and
focuses on testing one treatment against a specific target,
regardless of disease types [4]. It allows testing of a new
drug against various cancers at the same time. The term
“basket” refers to the fusion of potentially different can-
cers (according to the common classification by the body
organ where they begin [6] or by their histological type
of origin [7, 8]) into one similar disease at the molecular
level.
A common example of a basket trial is an ongoing
phase II NCI-MATCH (Molecular Analysis for Therapy
Choice, NCT02465060) trial launched in 2015 by the US
National Cancer Institute (NCI) [9]. The general schema
of this study is shown in Fig. 2.
Patients with any advanced solid tumors, lymph-
omas or myeloma who have progressed on standard
of care or for whom there is no standard treatment
may be eligible to register to NCI-MATCH trial [9].
After enrollment, samples obtained from a biopsy are
screened to determine whether the tumors contain spe-
cific genetic changes that can be matched to the drugs
being studied in the trial. Then, patients are assigned to
the treatment arms [11]. If more than one genetic ab-
normality is found, the patient is assigned to the arm
that is the most promising for a direct therapeutic
benefit or to the arm that starts the earliest to provide
treatment as soon as possible [4]. If the disease pro-
gresses, the patient may be treated with other drugs
tested in the study or undergo a repeat biopsy [5]. The
trial’s primary endpoint is the objective response (OR)
rate, which includes complete or partial response to
treatment, and the secondary endpoint is progression-
free survival (PFS) at 6 months of treatment with
targeted study agent [9].
The initial results for 3 NCI-MATCH arms are summa-
rized in Table 1. The enrollment in this trial is dynamic-
ally expanding and new arms are open for accrual.
Fig. 1 General schema dividing master protocol into a basket or an umbrella trial. A basket trial enrolls patients with different cancer types but
sharing one common molecular alteration. They receive one treatment. An umbrella trial enrolls patients sharing the same cancer type but
different molecular alteration. The treatment is adjusted to the specific target
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Umbrella trial
An umbrella trial enrolls patients with one cancer type
but with different genetic changes within each tumor
(Fig. 1). It consists of many small sub-trials to test mul-
tiple drugs simultaneously in one large trial [2, 6]. Pa-
tients receive different targeting treatments matched to
their genetic aberration. The term “umbrella” refers to
separation of one alleged cancer into many sub-cancers
depending on their molecular features. There is also a
“default arm” which assigns patients without a specific
marker to receive standard treatment [6].
The Lung-MAP: S1400 Phase II/III Biomarker-Driven
Master Protocol for Second Line Therapy of Squamous
Cell Lung Cancer (NCT02154490) is an example of an on-
going umbrella study sponsored by Southwest Oncology
Group (SWOG) [15]. Its general schema at the time of
opening in 2014 with five original treatment sub-trials is
presented in Fig. 3.
Adult patients with advanced squamous cell cancer
(SCCA) of the lung who progressed on first-line platinum-
based therapy could be eligible to enroll into the Lung-
MAP trial. After genomic screening of their tumor sample,
Fig. 2 The schema of NCI-MATCH study design. The biopsy material derived from registered patients is characterized for specific pre-defined
mutations via genetic sequencing. If an actionable mutation is detected, patients are assigned to 1 of 30 treatment sub-protocols. Those
experiencing disease progression or serious adverse events undergo review of their previous biopsy results or undergo another biopsy to search
for alternative treatment [10]
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they were initially assigned to one of the five independent
sub-studies (four targeted therapies and one non-match
therapy) and randomized to receive either an investigational
drug or standard treatment. If more than one genetic
change was found, they were assigned to a sub-trial based
on a pre-defined algorithm that balanced accrual among
sub-studies. If no actionable marker was detected, they
were enrolled to the non-match sub-trial, allowing all eli-
gible patients to be treated [16]. The trial’s primary end-
point was response rate [17]. The decision to either close a
sub-study or move to a phase III registration trial was based
on the interim analysis of each phase II sub-trial [16].
Since June 16, 2017 all of these five original sub-stud-
ies have been closed to accrual and their interim results
are presented in Table 2 [17]. Randomization has been
amended [17] and currently, four new sub-studies
(S1400F, S1400G, S1400I and S1400K) are a part of the
Lung-MAP trial and are open for accrual.
Main text
Scientific validity
Scientific validity of the research is one of the essential
ethical requirements [18] as the overarching goal of a
clinical trial is to provide evidence that can support clin-
ical decision-making [19]. Here, we outline some of the
major challenges referring to scientific validity in basket
and umbrella trials.
The first issue that can be a threat to scientific validity is
the design of a treatment that matches only a single muta-
tion, while tumors may harbor multiple mutations at a
time. Cancer’s heterogeneity can be distinguished not only
within the primary tumor (intratumoral heterogeneity),
but also between the primary tumor and its metastases
(intertumoral heterogeneity) and between patients (inter-
patient heterogeneity) [4, 20, 21], which indicates that
every tumor is unique. Thus, focusing only on molecular
therapy targeting single mutation without considering the
complexity of tumor biology, may introduce bias. It is
unclear how many patients in NCI-MATCH and Lung-
MAP trials are diagnosed to harbor more than one muta-
tion. There may be more patients that only partially match
the intervention (harbor multiple genetic changes) than
the ones that totally match (harbor only one genetic
change). Moreover, in a trial with randomization, like in
the Lung-MAP trial, patients in both arms (experimental
and standard of care) should harbor similar genetic
changes within a tumor to be comparable and represent
the same patient population. If the complexity and hetero-
geneity of tumors are neglected, the result may be a treat-
ment failure and the impossibility to produce scientifically
reliable findings.
The flexible structure of basket and umbrella trials al-
lows for testing multiple interventions simultaneously,
closing ineffective ones and opening new ones without
writing a new protocol, which saves time and financial
resources. Nevertheless, after closing a treatment, the re-
sults of the trial sub-study should be published as soon
as possible as a full journal publication because the pro-
found results of completed clinical trials are crucial for
decision making in evidence-based medicine and inform
future research. Unfortunately, summary results of NCI-
MATCH and Lung-MAP sub-studies are incomplete.
For example, it is hard to say in which arm of the five
sub-studies in the Lung-MAP study subjects benefitted
more (intervention or standard of care), because re-
sponse rates in the standard of care arms have not yet
been published (Table 2). Since we do not know whether
responses are higher or lower in the standard of care
arm, we claim that the risk of publication bias is the sec-
ond challenge of the scientific validity requirement.
The flexibility enables also for changes in the protocol.
Giving the exact example is the initial design of the
Lung-MAP trial as a study including randomization to a
control arm, which was further modified during the trial
into single-arm study [17]. There is no explanation why
it was changed. This can mean that the design was
Table 1 Summary results of three NCI-MATCH sub-studies [12–14]
Sub-study Pts enrolled N Pts evaluable
for response N
PR
(%)
SD
(%)
PD
(%)
PFS6 rate
(%)
Pts evaluable
for toxicity N
AEs
(%)
Grade 3/4
AEs (%)
Comments
Arm W: Pts with FGFR1–3
mutation or translocation receive
FGFR Inhibitor AZD4547 [12]
52 41 5 51 44 17 49 80 49 Failed to meet its primary
endpoint
Arm Q: Pts with HER2
amplification receive
trastuzumab emtansine [13]
N/R 37 8.1 43 N/R 24.8 N/R N/R N/R Failed to meet its primary
endpoint
Arm I: Pts with PIK3CA mutation
without RAS mutation or PTEN
loss receive taselisib [14]
65 N/R 0 N/R N/R 27 N/R N/R N/R Failed to meet its primary
endpoint; Co-occurring
mutations were detected
in 67% of tumors; 11% of
pts. discontinued taselisib
because of toxicity
AEs Adverse events, N/R Not reported, OR Objective response, PD Progressive disease, PFS6 Progression-free survival at 6 months of treatment, PR
Partial response, Pts Patients, SD Stable disease
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flawed from the beginning and no one had foreseen that.
The freedom for unexplained modifications in the proto-
col is a third serious threat to scientific validity.
The main advantage of basket trials is that patients
with rare cancers have the opportunity to be enrolled
into the study. For example, in the NCI-MATCH trial,
about 61% of patients have less common tumors [22].
However, a fourth serious issue referred to scientific val-
idity is insufficient patient accrual to treatment arms,
which may affect statistical methods and power and op-
pugn the reliability of the findings. For instance, in the
NCI-MATCH trial only 8 of the 30 sub-studies reached
the minimum patient accrual goal of 35 [23]. A research
that cannot enroll sufficient subjects cannot generate
valid scientific knowledge and is unethical [3]. Further-
more, waiting for more patients that harbor a specific
mutation prolongs the study and delays the publication
of trial results. There are also doubts whether drugs
Fig. 3 The schema of the Lung-MAP study design with five initial sub-studies. Adult patients with recurrent or metastatic squamous cell
carcinoma (SCC) after progression on first-line platinum-based chemotherapy could be eligible to register in the Lung-MAP trial. After signing an
informed consent, their archival or fresh tumor biopsy sample was screened for genetic aberrations. Results of genomic testing were returned
within 16 days. Then, all patients were originally assigned to one of five sub-studies and they were randomized to receive either standard of care
or a specific agent tailored to their alteration. One of these sub-trials was called a “non-match” sub-study and it enrolled patients whose tumors
did not harbor any of the genetic aberrations tested in other sub-studies [15, 16]
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tested on an insufficient number of patients could be ap-
proved without confirmed efficacy based on surrogate
endpoints which are considered low-grade evidence [24].
Benefits and risks
Another important ethical requirement of conducting
clinical trials is a favorable risk/benefit ratio, which is met
when: 1) the risk for participants is minimized; 2) the ex-
pected benefits are maximized; and 3) the possible benefits
to participants and society outweigh or are proportional
to the risks associated with participation in the study. The
risk-benefit proportionality criterion considers the funda-
mental ethical principles of non-maleficence and benefi-
cence. It also serves as a protection for participants
against their exploitation [3].
There are three types of possible benefit in clinical tri-
als: aspirational, direct and collateral [25]. Aspirational
benefit is the benefit to society and to future patients,
which arises from the results of the study [25]. Novel
clinical trials serve as exploratory trials of both tumor
and pathways and they can gain important knowledge,
which can be used in future trials to develop effective
therapies. Thus, it is extremely important that the results
of a trial are published after each sub-trial completes.
Moreover, the aspects mentioned before in the scientific
validity section: the heterogeneity of tumors harboring
multiple mutations, problems with sufficient patient ac-
crual, risk of publication bias may generate unreliable
and unpowered findings, which negatively influences the
aspirational benefit, wastes resources and negatively af-
fects decision making in medicine [18].
Direct benefit is the benefit to research subjects arising
from receiving the intervention being studied [25]. In can-
cer trials an optimal direct benefit could be the one
achievable in patient-centered outcomes, such as overall
survival (OS) and/or quality of life (QoL) [26]. However,
in basket and umbrella trials the main measured outcomes
are surrogate endpoints such as: progression-free survival
(PFS), time to progression (TTP), tumor shrinkage, the
percentage of patients responding to a drug or biomarkers
that can predict clinical outcomes like survival. Surrogate
endpoints substitute clinically meaningful endpoints and
they are used to indicate whether treatment works. The
use of surrogate endpoints in certain phases of research is
justified [2, 24, 26] and their advantage is that they can
yield information about the effect of a drug more rapidly
than long-term clinical outcomes. Unfortunately, there is
recently mounting evidence illustrating that surrogate
endpoints do not necessarily translate to patient-centered
outcomes [24, 27–29]. This also means that the direct
benefit achieved by participants of umbrella and basket
trials is arguable.
Other data suggest that the minority of patients who
have been treated with genome-driven therapy benefited
to date [30]. However, other findings show that overall
response rate in all published basket trials in cancer medi-
cine until March 2018 was 25%, which seems very promis-
ing [31]. But published results of NCI-MATCH and
Lung-MAP trials are not equally promising. In NCI-
MATCH, all three arms (Table 1) failed to meet their pri-
mary endpoint (25% or more of the patients whose tumors
have a complete or partial response to treatment).
Table 2 Summary results of five initial Lung-MAP sub-studies [17]
Sub-study ClinicalTrials.gov
identifier
Final accrual Response rate to
investigational therapy N (%)
Comment
S1400A (non-match) NCT02766335 Total: 116 11 (16) Administratively closed to enable
activation of a new non-match study
Chemotherapy: 38
MEDI4736: 78
S1400B NCT02785913 Total: 39 1 (4) Failed to meet its primary endpoint,
closed at interim futility analysis
Chemotherapy: 8
GDC-0032: 31
S1400C NCT02785939 Total: 54 2 (6) Failed to meet its primary endpoint,
closed at interim futility analysis
Chemotherapy: 17
Palbociclib: 37
S1400D NCT02965378 Total: 45 2 (7) Failed to meet its primary endpoint,
closed at interim futility analysis
Chemotherapy: 10
AZD4547: 35
S1400E NCT02926638 Total: 9 N/A Closed early due to discontinuation
of development of rilotumumab
Erlotinib: 5
Erlotinib + Rilotumumab: 4
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Nevertheless, there were 17% or more patients with
prolonged stable disease. Similarly, in the Lung-MAP
study (Table 2),v all of the five subprotocols failed to
meet their primary endpoint (25% or more of the patients
whose tumors have a complete or partial response to
treatment). Surprisingly, participants in the non-match
sub-study benefitted more than the ones who matched,
which may indicate that the treatment adjusted to a gen-
etic change is less effective than the treatment that does
not match.
The third type of benefit – “collateral” benefit, refers
to benefit arising from being a research subject, like free
medical care or the personal gratification of altruism
[25]. This kind of benefit is easily discernible in basket
and umbrella trials as thousands of patients may be
screened and find out more about their disease and take
part in the research process. However, not every patient
can be screened as some tumors are too small to be col-
lected for research purposes [32]. Even if they are eli-
gible to be screened, the genetic profiling may fail to
detect any actionable mutation. If there is an alteration,
sometimes there is a lack of standard treatment or on-
going trial to offer. For example, in the Lung-MAP trial
every patient can be treated, because a “non-match”
study exists, unlike in the NCI-MATCH study, in which
patients without actionable mutations are out of the
study. In the NCI-MATCH trial 5963 tumors were
screened for 30 treatment arms from opening in 2015
thru 16th July 2017 and in 5546 (93%) the assay was suc-
cessful. Among them, 998 patients were assigned to
matched interventions, but only 689 (69%) enrolled in
all treatment arms, which gives 12% of all screened pa-
tients who finally started the therapy [22].
Despite the fact that basket and umbrella trials allow
for recruitment of patients with rare malignancies, which
can be considered as their main advantage, it is unclear
why only some provide a “default arm” and some do
not. It may be worth to explore various rare tumors and
enable patients with no standard treatment options to be
part of the research and contribute to gaining knowledge
that can be used to develop new therapies.
There are many different types of risk or harm to re-
search subjects, such as: physical, psychological, economic,
legal or dignitary [33]. The first two types - physical and
psychological, may appear at different stages during the
research process of basket and umbrella trials. In these
studies, some invasive procedures e.g., biopsy or surgical re-
section are required to collect an adequate tumor sample
for evaluation via genetic profiling. Patients only take part
in this research process if it is feasible and supposedly safe
to obtain tumor material for molecular and genomic stud-
ies [32]. A tumor biopsy may be considered safe, but it can
be stressful and uncomfortable for volunteers [34]. There is
always a possibility of complications, especially when
dealing with patients who progressed after chemotherapy
and their organisms are weak. In turn, Overman et al. [35]
raise issues with underreporting of results derived from re-
search biopsies and provide recommendations to improve
such reporting. Biopsy findings are particularly important
in basket and umbrella trial designs as they are crucial to
include or exclude a large number of potential participants
from further steps of the study and they are supposed to
generate knowledge and justify the risk.
While large volumes of tumor tissue are required for as-
sessment and optimal diagnosis, sometimes depending on
the localization of the lesion, it is challenging or even im-
possible to obtain a sufficient amount of tissue. Moreover,
a biopsy material may be of low quality and/or not accur-
ately capture the complete genomic landscape of the
patient’s cancer, so only a limited geographical region of
tumor is analyzed [21]. These both may result in mis-
matching and assigning the patient to inappropriate study
arm and therefore, pose harm. Allocation to a substandard
treatment either after a biomarker test result or after
randomization is the most serious problem in basket and
umbrella trials. They are designed to test one targeted
treatment against one specific abnormality found in the
patient’s tumor but there are instances where more than
one genetic change is diagnosed. Such precarious single-
target treatment may be insufficient and not match the
entire heterogeneous tumor, resulting in disease progres-
sion. In this case, the intervention that targets the whole
tumor may be more beneficial to the participant.
Consider the case of two patients enrolled to e.g.,
S1400B sub-study (Table 2): one with a single genetic de-
fect, and the other with multiple genetic changes clearly
identified, who are randomized to receive either chemo-
therapy or experimental intervention. If the first one is
allocated to the chemotherapy arm and the second to the
experimental arm it may not only be disadvantageous for
them to obtain direct therapeutic benefit but also for ac-
quiring reliable and reproducible results.
The process of screening and genome sequencing must
be efficient and quick. From the patient’s perspective, the
screening delay means being untreated for 2 weeks while
awaiting results. For some oncology patients, 14 or 16 days
is not many, for others every single day may be crucial
and full of hope, stress and uncertainty, whereas some
may even not survive to be enrolled.
Other risks in basket and umbrella trials are the same as
in other areas of medicine. For example, there is a prob-
lem how to cope with any incidental findings found dur-
ing genetic sequencing, which contain important health or
reproductive information about participants [32]. More-
over, the recruitment of thousands of participants gener-
ates a huge amount of data that must not only be rapidly
processed, but also reliably and safely stored, so that un-
desirable people have no access to it.
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The ethics of research with human beings demands
that patient-subject burdens are redeemed by gains in
generalizable knowledge. Taking into consideration both
risks and benefits, we claim that there is a low chance of
direct therapeutic benefit to participants due to the
major flaw in the design of these trials, which include
patients with multiple genetic aberrations and test treat-
ments against a single aberration, which can harm pa-
tients and may fail in gaining reliable findings. If this
flaw is reduced by including patients with only one ac-
tionable mutation, then the risks can be justifiable.
Informed consent
Informed consent is the cornerstone ethical principle of
biomedical research [19] and it can be challenged in
oncology clinical trials, including basket and umbrella
trials. The perception of patients with life-threatening
diseases is often affected by a desperate hope for the
therapeutic benefit. They may understand the nature of
the research process, but sometimes a clinical trial is
their last hope and the last chance for any therapeutic
benefit. This is where therapeutic misunderstanding can
appear [36].
One such misunderstanding, the main ethical concern
in cancer research, is a therapeutic misconception defined
as “the belief that the purpose of a clinical trial is to bene-
fit the individual patient rather than to gather data for the
purpose of contributing to scientific knowledge” [37]. This
tendency is common in all types of trials and can affect
both patients willing to participate in a trial, and investiga-
tors/physicians who feel a therapeutic duty to deliver the
best medical care to patients.
In basket and umbrella trial designs patients are divided
into two groups – those who “match” and “not match” the
experimental treatment. In the NCI-MATCH study, only
the group that “matches” remains in the trial and receives
intervention and the rest are excluded from the trial, while
in the Lung-MAP study both those who match and do not
match are treated. We think that the group that “matches”
may have overestimated expectations and personal convic-
tion that intervention is directly adjusted to each individ-
ual, although all subjects are treated according to the
protocol. The same goes for another form of misunder-
standing called “therapeutic misestimation”, which is de-
scribed as “misunderstanding the probability of direct
benefit or harms that may result from participating in
research” [38] - subjects that “match” may overestimate
potential chances to receive benefit and underestimate the
risks, because they are “the chosen ones”. The problem of
such misunderstandings can be intensified in trials with
“non-match” sub-study without blinding of participants
where everyone knows to which sub-trial they were
assigned. In these trials, subjects in arms that “matched”
may be 100% confident that they receive the treatment
that best matches their disease and they will surely benefit,
while patients in “non-match” may believe that the ther-
apy they receive does not work at all, which can pose
problems with reporting adverse events and assessing
therapy efficacy.
What can even deepen therapeutic misunderstandings
among those who want to participate in novel precision
medicine trials is the excessive use of phrases like “person-
alized” or “individualized medicine”, and “tailored” therapy.
Such terminology can be misleading, and falsely indicate
that the trial’s goal is to provide personalized care with re-
gard to the patient’s best interest standard and direct thera-
peutic benefit. We propose to avoid such phrases in master
protocols and use more generalizable ones, such as “therapy
based on genomics”.
We suggest that the problem of misunderstandings in
precision medicine trials should be evaluated and reduced
in view of giving valid informed consent. Without fully
understanding the purpose of the trial as well as the real
consequences of participation, a subject’s informed deci-
sion to take part in research is ethically challenged. Add-
itionally, patients should be provided with information
about the prospect of benefitting from the screening
process while considering to enter the study. They may
not be aware that after the screening process they may not
be enrolled into the study, but they may have the oppor-
tunity to undergo another already approved treatment.
The exclusion from being a trial participant does mean
that they cannot be treated after all. Still, it is unclear how
many patients in basket and umbrella trials do not enter
the study because there are better treatment options for
them and how many of them remain untreated due to the
lack of any existing therapy.
Conclusions
Basket and umbrella trials in oncology offer a new trial de-
sign aiming to test different types of treatments in an
innovative and effective way. A new, flexible design, tar-
geting single molecular alteration supposed to solve prob-
lems with recruitment and enable participation of patients
with rare cancers turns out to be ethically challenged. An
unusual flexibility and major differences in published re-
sults compared with the trials’ protocols, use of misleading
terminology (e.g. “personalized medicine”), and complex-
ity of malignancies are the examples of major concerns
referring to ethically sensitive aspects: scientific validity,
risk-benefit ratio and informed consent.
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